Melacine

consists of a lysate of two homogenized melanoma cell lines that are combined with the adjuvant DETOX (detoxified Freund's adjuvant); tradename; for active specific immunotherapy for melanoma

Networked: 13 relevant articles (1 outcomes, 8 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Sondak, Vernon K: 4 articles (10/2014 - 04/2002)
2.	Sosman, Jeffrey A: 4 articles (10/2014 - 04/2002)
3.	Mitchell, Malcolm S: 4 articles (11/2003 - 01/2002)
4.	Flaherty, Lawrence E: 2 articles (10/2014 - 04/2002)
5.	Kempf, Raymond A: 2 articles (10/2014 - 04/2002)
6.	Thompson, John A: 2 articles (10/2014 - 04/2002)
7.	Unger, Joseph M: 2 articles (10/2014 - 04/2002)
8.	Carson, William E: 1 article (10/2014)
9.	Othus, Megan: 1 article (10/2014)
10.	Porter, Mark J: 1 article (10/2014)

Related Diseases

1.	Melanoma (Melanoma, Malignant) 10/01/2014 - "Similar associations were observed in S9035, a phase III adjuvant trial evaluating Melacine for 2 years compared with observation in patients with stage II melanoma. " 12/01/1998 - "These results stimulated current multicenter trials in stage IV and resected stage III melanoma of Melacine and IFN-alpha in combination versus IFN-alpha alone. " 06/01/2003 - "Melacine (Corixa Corp.) is an allogeneic melanoma tumor cell lysate combined with the adjuvant DETOX. " 12/01/2003 - "A phase III trial indicated a survival benefit for Melacine in the subset of melanoma patients who express the HLA class I antigens A2 and/or HLA-C3. " 12/01/2002 - "In this Phase II trial, the combination of cyclophosphamide, Melacine, and IFNalpha was tested in metastatic malignant melanoma. "
2.	Neoplasms (Cancer) 12/01/2002 - "Melacine was administered at a dose of 2 x 10(7) tumor cell equivalents per dose admixed with 0.25 ml of Detox-PC s.c. " 06/01/2003 - "Melacine (Corixa Corp.) is an allogeneic melanoma tumor cell lysate combined with the adjuvant DETOX. " 01/01/2002 - "A combination of interferon-alpha2b and Melacine appears to enhance the anti-tumor response in advanced (stage IV) disease, and is being tested in a large randomized controlled trial in resected stage III disease. " 02/01/1994 - "These data suggest an additive effect of active specific immunotherapy and IFN-alfa on the objective response rate, perhaps through upregulation of HLA molecules and tumor-associated antigens on the tumor cell by IFN-alfa, after immunization of the patient by Melacine. " 12/01/2003 - "Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine."
3.	Communicable Diseases (Infectious Diseases) 10/01/2001 - "MPL has been administered to many subjects in clinical trials as an adjuvant component of infectious disease vaccines and is currently a component of a licensed cancer vaccine, Melacine (Corixa Inc., Schering Plough). "

Related Drugs and Biologics

1.	Vaccines
2.	Histocompatibility Antigens Class I
3.	Cancer Vaccines
4.	Antigens
5.	Immunologic Adjuvants (Immunologic Adjuvant)
6.	HLA Antigens (Human Leukocyte Antigens)
7.	Haptens
8.	Cyclophosphamide (Cytoxan)
9.	polyvalent melanoma cell vaccine
10.	HLA-A2 Antigen (HLA A2 Antigen)

Related Therapies and Procedures

1.	Injections
2.	Immunotherapy